Knoll Report issue

Contributed to NME For profit Phase 3
Founded: Ludwigshafen Germany (1886)
Status: Acquired by Abbott (2000)

Organization Overview

First Clinical Trial
2000
NCT00272103
First Marketed Drug
1943
hydrocodone (hycodan)
First NDA Approval
1943
hydrocodone (hycodan)
Last Known Activity
2000

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Knoll Pharmaceuticals, Germany (now Abbott)

Active Ingredients

Marketed Drugs (3)

hydrocodone (hycodan) (1943 NDA)

levothyroxine (Synthroid) (1955 NDA)

trandolapril (mavik) (NDA)

Drugs in Phase 3 Trials (1)

itropride (1 trial)

Indications

Approved Indications


 

Acute Pain

Congenital Hypothyroidism

Goiter

Heart Failure

Hypertension

Hypothyroidism

Pain

Thyroid Neoplasms

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dyspepsia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1